Institute for Healthier Living Abu Dhabi and Singleron Partner for Advanced Precision Medicine
Aiming to accelerate precision medicine by leveraging single-cell multi-omics technologies for improved diagnostics and personalized treatments.
The Institute for Healthier Living Abu Dhabi (IHLAD), renowned as the world’s first Healthy Longevity Medicine Centre, has joined forces with Singleron Biotechnologies, a global frontrunner in single-cell multi-omics solutions, to unveil a transformative joint venture: AD-Omics. This new entity is set to redefine the landscape of precision diagnostics and personalized medicine across the Middle East, supporting the UAE’s national vision for innovation-driven, world-class healthcare.
Commenting on the joint venture, Dr. Nicole Sirotin, Chief Executive Officer of IHLAD, remarked: “Precision medicine tailors treatment plans based on individual genetic, environmental, and lifestyle factors. Singleron’s expertise in single-cell multi-omics technologies provides unparalleled insights into cellular behaviour, enabling precise diagnosis and treatment strategies. Paired with IHLAD’s innovation, population health and future clinical offerings committed to advancing human longevity, the launch of AD-Omics is a significant milestone in our mission to make these groundbreaking advancements accessible to patients across the Middle East. Together, we aim to revolutionize how diseases are understood and treated, giving patients access to personalized treatments that improve quality of life and longevity.”
Dr. Nan Fang, Chief Executive Officer of Singleron, added: “Our mission has always been to make single-cell technologies widely available for better healthcare solutions. By partnering with IHLAD on AD-Omics, we are not only expanding our footprint into the Middle East but also ensuring that our innovations are utilized to their fullest potential to transform lives.”
Uniting Innovation and Expertise
AD-Omics emerges from the synergy between IHLAD’s deep domain knowledge in healthy longevity science and Singleron’s cutting-edge technology in single-cell analysis. This powerful partnership is dedicated to delivering region-specific medical breakthroughs by integrating next-generation technologies.
Advancing Cellular and Genomic Science
One of AD-Omics’ primary goals is to introduce Singleron’s single-cell sequencing capabilities to the Middle East. These technologies will help unlock unprecedented insights into human biology, ageing, and disease mechanisms, paving the way for novel clinical applications.
Transforming Chronic Disease Management
By applying precision medicine frameworks, AD-Omics aims to revolutionize how chronic conditions like cancer, diabetes, and cardiovascular diseases are diagnosed and treated. Tailored therapies based on genomic data will improve treatment accuracy and patient outcomes.
Building Knowledge Hubs and Research Capacity
Education and research will be central to AD-Omics' mission. The joint venture plans to establish Centres of Excellence throughout the region, empowering healthcare professionals with the training and tools to lead in the field of precision medicine.
Leveraging AI for Predictive Healthcare
Artificial intelligence will play a pivotal role in the venture, enabling sophisticated analysis of complex multi-omics datasets. These AI-driven insights will support early detection, personalized treatment strategies, and predictive modelling of disease progression.
Expanding Market Access to Multi-Omics Solutions
Beyond clinical impact, AD-Omics will provide the region with access to high-quality single-cell and multi-omics solutions, ranging from research products to fully integrated services, helping to build a self-sustaining ecosystem for advanced medical technology in the Middle East.
A Vision for the Future of Healthcare
Through this strategic collaboration, IHLAD and Singleron reaffirm their dedication to pushing the boundaries of medical science. Together, they aim to build a healthcare future where precision, personalization, and innovation define every patient experience across the region.
Comments